Skyepharma's asthma delivery system could be a $500m blockbuster
Monday 12 January 2009
There are countless companies that are no doubt glad to see the back of 2008, even if they are a little uncertain about what 2009 might bring. One of them is certainly the biotech group Skyepharma, whose annus horribilis last year saw its share price collapse under the weight of two convertible bonds worth £89m, on which investors had put options, exercisable this year and next.
The shares dropped from a year high of 744p to 116p, with some analysts predicting last year that had the bond investors so desired they could have forced the company out of business.
Indeed, last July, when the group's share price fell 32 per cent in one day – in pre-Lehman-collapse times, such falls were still considered astronomical – as talks between the company and its bondholders collapsed, the writing appeared to be on the wall.
So what a difference a few months makes. The group has always relied on its potential blockbuster asthma delivery system Flutiform, which was perhaps what saved the group from collapse, as investors recognised that Skyepharma was worth saving, and eventually renegotiated the terms of the deal by putting back the put dates on the bonds by several years.
Since the deal was struck, the news has got even better. Last week, a treatment called Lodotra, which treats arthritis and joint stiffness, was given approval to be used in Europe. The medicine uses Skyepharma's "Geoclock" technology, which ensures that the treatment takes effect at the necessary times.
While the group will not be able to suddenly pay back those troublesome bonds on the back of Lodotra's success – the company will receive a single-digit percentage royalty on net sales – it is at least a further step back from the precipice.
The group is desperately hoping that its filing for Food and Drug Administration approval for Flutiform, which is expected in before the end of March, is successful.
While the earnings from Geoclock will be welcomed, it is still Flutiform that excites analysts, with those at Piper Jaffray saying that the treatment could be worth as much as $500m (£328m).
Presents unwrapped, turkey gobbled... it's time to relax
Video: It is the type of thing no parent wants to hear
- 1 Exodus Gods and Kings casting controversy: Ridley Scott would never cast 'Mohammad so-and-so from such-and-such' in lead role
- 2 This letter from a reader explains why women can’t play football
- 3 'You should come to my house and eat cheeses with me': 4-year-old sends adorable love letter to girl at school
- 4 Scientists predict green energy revolution after incredible new graphene discoveries
- 5 Michael Buerk wishes he killed Jimmy Savile when he had the chance - by pushing him overboard a cruise ship
Black Friday 2014: Opening times for Asda, John Lewis, GAME, PC World and Argos
Sean Abbott: Messages of support flood in for bowler after death of Phil Hughes
Plebgate: Andrew Mitchell’s reputation in tatters as judge rules he used the word ‘pleb’
Dr Lam Hoe Yeoh: Voyeur doctor jailed for eight years after using network of hidden cameras to film patients, colleagues and friends on the toilet
'You should come to my house and eat cheeses with me': 4-year-old sends adorable love letter to girl at school
Ukip says babies born to immigrants in the UK should be classed as migrants – which would include Nigel Farage’s own children
Obama: The only people with the right to object to immigration are Native Americans
The young are the new poor: Sharp increase in number of under-25s living in poverty, while over-65s are better off than ever
Tamir Rice: 12-year-old boy playing with fake gun dies after being shot by Ohio police
Ukip mocked after mistaking Westminster Cathedral – for a mosque
Sarah Vine criticises lesbian mother Jack Monroe: 'If she was unsure about her sexuality, she should have taken greater precautions'
iJobs Money & Business
£50000 - £100000 per annum + benefits: h2 Recruit Ltd: Are you a high achievin...
£35000 - £100000 per annum + benefits: h2 Recruit Ltd: An award winning, marke...
£19000 - £24000 per annum: Recruitment Genius: Due to our clients continuing s...
£20000 - £22000 per annum: Argyll Scott International: Service Desk Analyst Re...